Mirikizumab Dosage

Medically reviewed by Drugs.com. Last updated on Jan 16, 2024.

Usual Adult Dose for Ulcerative Colitis

Induction dose: 300 mg IV over at least 30 minutes at weeks 0, 4, and 8
Maintenance dose: 200 mg subcutaneously at week 12, and every 4 weeks thereafter

Comments:

• The 200 mg subcutaneous dose should be administered as 2 consecutive 100 mg prefilled injections.

Use: For the treatment of moderately and severely active ulcerative colitis

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

CONTRAINDICATIONS: History of serious hypersensitivity reaction to this drug or any of its excipients

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

• IV formulation is intended for administration by a healthcare provider using aseptic technique.
• Full maintenance subcutaneous dose requires 2 prefilled pens.
• Prefilled pens should be used under the supervision of a healthcare professional.
• Health care professionals should provide proper training to patients and/or caregivers on injection techniques. Patients may self-inject after training.
• Subcutaneous injection sites include the abdomen, thigh, and back of the upper arm. Instruct patients to inject in a different location every time.
• Do not inject in areas where the skin is tender, bruised, erythematous, or indurated.
• If a dose is missed, administer the dose as soon as possible. Thereafter, resume doing every 4 weeks.

Storage requirements:

• Store diluted infusion solution in the refrigerator at 2C to 8C (36F to 46F). Do not freeze.
• Use diluted infusion solution within 48 hours, at a maximum of 5 hours at non-refrigerated temperatures, and not to exceed 25C (77F).
• Keep away from direct heat or light.
• Prefilled pens should be kept in the original carton and stored in the refrigerator at 2C to 8C (36F to 46F); they may also be stored at room temperature up to 30C (86F) for up to 2 weeks.
• Do not shake the prefilled pens.

Reconstitution/preparation techniques:

• The manufacturer product information should be consulted.
• Remove the prefilled pen from refrigerator and leave at room temperature for 30 minutes before use.

Monitoring:

• Infection: Tuberculosis (prior to initiating therapy and after treatment)
• Hepatic: Liver function (prior to and during therapy)
• Immunization: Age-appropriate vaccinations (prior to initiating therapy)

Patient advice:

• Read the FDA-approved patient labeling (Medication Guide and Instructions for Use).
• Complete proper training with your health care provider prior to self-administering subcutaneous injection.
• Seek immediate medical attention if you experience symptoms of serious hypersensitivity reactions.
• Vaccination with live vaccine is not recommended during treatment and immediately prior to or after treatment with this drug.
• Contact your healthcare provider immediately if you have:
• signs of infection such as fever
• symptoms suggestive of tuberculosis such as fever, cough, or difficulty breathing
• symptoms suggestive of liver injury such as unexplained rash, nausea, vomiting, abdominal pain, fatigue, weight loss, or jaundice and/or dark urine
• A pregnancy registry is available.

See also:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer